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Biochemistry
I2B is a small cytosolic protein that participates in vacuole fusion
PAUL SLUSAREWICZ*†, ZUOYU XU*, KIMBERLY SEEFELD, ALBERT HAAS‡, AND WILLIAM T. WICKNER§
Department of Biochemistry, Dartmouth Medical School, Hanover, NH 03755-3844
Contributed by William T. Wickner, March 16, 1997
ABSTRACT Saccharomyces cerevisiae vacuole inheritance
requires two low molecular weight activities, LMA1 and
LMA2. LMA1 is a heterodimer of thioredoxin and protease B
inhibitor 2 (I2B). Here we show that the second low molecular
weight activity (LMA2) is monomeric I2B. Though LMA2yI2B
was initially identified as a protease B inhibitor, this protease
inhibitor activity is not related to its ability to promote vacuole
fusion: (i) Low Mr protease B inhibitors cannot substitute for
LMA1 or LMA 2, (ii) LMA1 and LMA2 promote the fusion of
vacuoles from a strain that has no protease B, (iii) low
concentrations of LMA2 that fully inhibit protease B do not
promote vacuole fusion, and (iv) LMA1, in which I2B is
complexed with thioredoxin, is far more active than LMA2yI2B
in promoting vacuole fusion and far less active in inhibiting
protease B. These studies establish a new function for I2B.
Organelle inheritance is tightly regulated during the cell cycle
(1, 2). In Saccharomyces cerevisiae (2), low copy-number
organelles such as the nucleus (3, 4) and mitochondria (5, 6)
are segregated into the bud. We have been studying the
inheritance of the yeast vacuole. In early S-phase, the maternal
vacuole projects a striking array of tubular-vesicular material,
termed the segregation structure, into the bud (7). This
vacuolar exchange continues until the onset of M-phase. The
vacuolar vesicles in the bud then fuse to form the daughter cell
organelle.
Several vac (vacuole inheritance) mutants are defective in
this process (8–12). In a biochemical approach, we have
developed an assay to study the process of vacuole inheritance
in vitro (13–15). Isolated vacuoles, when incubated with ATP
and cytosol, form tubular extensions that resemble the segre-
gation structures seen in vivo (13). These structures are
physiologically relevant, as they are not produced from vacu-
oles prepared from vac mutant strains.
Vacuole fusion, the terminal step of the inheritance mech-
anism, is also observed in vitro, requires VAC gene products,
and can be monitored in a quantitative assay. This reaction,
which requires ATP and cytosol, relies on the mixing of
vacuole contents after fusion (14, 15). For this assay, vacuoles
are purified from two strains. The first lacks the PHO8 gene,
which encodes vacuolar pro-alkaline phosphatase, but con-
tains the normal vacuolar proteases. The second lacks pro-
teinase A, the vacuolar maturation enzyme, and therefore
contains enzymatically inactive pro-alkaline phosphatase.
Upon membrane fusion and mixing of the vacuole contents,
the prophosphatase is proteolytically activated. Alkaline phos-
phatase activity, determined by colorimetric assay, is a direct
measure of membrane fusion.
Fusion of vacuoles requires the small GTPase protein Ypt7p
(16) and the membrane-trafficking proteins Sec17p (a-SNAP)
and Sec18p (NSF) (17, 18). All three factors act early in the
fusion pathway, where ATP-driven release of Sec17p by
Sec18p primes the vacuoles for Ypt7p-dependent docking (18,
19). After docking, these factors are no longer required for
membrane fusion.
Yeast cytosol contains several proteins that support vacuole
fusion (20). These include a high molecular weight activity and
two low molecular weight activities (LMA1 and LMA2).
LMA1 is a heterodimer of thioredoxin 1 and protease B
inhibitor 2 (I2B) and stabilizes vacuoles that have been ‘‘primed’’
by Sec 17p release (21). We now report that LMA2 is actually
I2B, free of thioredoxin, and show that LMA2, though less active
than LMA1, does not support vacuole fusion simply by inhib-
iting protease B.
MATERIALS AND METHODS
Yeast Strains. S. cerevisiae strains were: K91-1A (MATa
ura3 pho8::pAL134 pho13::pPH13 lys1) from Y. Kaneko (In-
stitute of Fermentation, Osaka); BJ 3505 (MATa pep4::HIS6
prb1-D1.6R HIS3 lys2–208 trp1-D101 ura3–52 gal2 can) and
DKY 6281 (MATa leu2-3 leau2-112 ura3-52 his3-D200 trp1-
D901 lys2–801 suc2-D9 pho8::TRP1) from D. Klionsky (Uni-
versity of California, Davis); YS18 (MATa ura3-5 his3-11
leu2-3,-112 canR); YPS19 (MATa Dpbi2::URA3) from D. Wolf
(University of Stuttgart, Stuttgart, Germany); EMY21-1C
(MATa TRX1 TRX2 Dlys2::HIS3 ura3-1 Dade3-100 ade2 trp1-1
leu2-3 112 his3-11 can1-100), and EMY21-8D (MATa
Dtrx1::TRP1 Dtrx2::LEU2) from E. Muller (University of
Washington, Seattle). Yeast were grown in YPD medium.
Materials. Oxalyticase was from Enzogenetics (Corvallis,
OR). ATP, GTP, DEAE-Dextran, Ficoll 400, Sephacryl
S-300HR, SP-Sepharose Fast Flow, PBE 94, and Polybuffer 96
were from Pharmacia. Creatine phosphokinase, creatine phos-
phate, Pipes, chymostatin, guanosine 59[g-thio]triphosphate
(GTP[gS]) and Pefabloc SC were fromBoehringerMannheim.
N-(3-triethylammoniumpropyl)-4-(p-diethylaminophenyl-
hexatrienyl) pyridinium dibromide (FM4-64) was from Mo-
lecular Probes. Coomassie brilliant blue R, polyvinylidene
difluoride membranes, and Protein Assay kit (using BSA as a
standard) were from Bio-Rad. Mastoparan was from Penin-
sula Laboratories and microcystin LR from LC Services
(Woburn, MA). Azocoll was from Calbiochem. LMA1 was
purified as described (20). His-tagged Sec18p and other re-
agents were prepared as described (16, 17).
Yeast Cytosol. For purification of I2B, K91-1A cells were
grown in 150L of YPD to OD600 5 3.0 and collected in a
Sharples centrifuge. Cells were suspended in 6 l of water at
238C, sedimented (5,000 3 g, 5 min, 48C), resuspended in 3 l
of cytosol buffer (20 mM PipeszKOH, pH 6y150 mM KOAcy
250 mM sorbitoly5 mM MgCl2), sedimented, resuspended in
250–300 ml of cytosol buffer and frozen by dropwise addition
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to liquid nitrogen. Cells were lysed in liquid nitrogen by
homogenization in a 5-l Waring blender. One quarter of the
frozen cells were processed at a time for 5 min each, with
occasional addition of liquid nitrogen. The lysed cell powder
was thawed in a 4 l Erlenmeyer flask under hot tap water. After
partial thawing, 200 mM phenylmethylsulfonyl f luoride in
isopropanol was added to a final concentration of 0.5 mM.
After centrifugation at 48C as above, the supernatants were
pooled. Mg-ATP and 1,0003 protease inhibitor cocktail
(1,0003 PIC; 200 mM Pefabloc SCy5 mg/ml leupeptiny500
mM 1,10-phenanthroliney5 mg/ml pepstatin A) were added to
0.1 mM and 23 final concentrations. The lysate was centri-
fuged (45Ti, 48C, 20 min) and supernatants were frozen as
droplets in liquid nitrogen.
Cytosol preparations from other yeast stains were either by
a smaller version of this procedure or by agitation with glass
beads (13). For heated cytosol supernantant (HCS), cytosol
was heated to 808C in a boiling water, kept at 808C for 4 min,
then cooled in an ice water bath. The precipitate was removed
by centrifugation (17,000 3 g, 30 min, 48C).
Colorimetric Vacuole Fusion Assay. Fusion assays were
described previously (20, 22), using salt-washed, frozen vacu-
oles and 17 ng of his-tagged recombinant Sec18p. One unit of
activity is the hydrolysis of 1 mmol p-nitrophenol phosphatey
minzmg of BJ 3505 vacuolar protein.
Inhibitors were used at the following concentrations: 1.5
mM GTP[gS], 22 mMmastoparan, 64 mgyml Gdi1p, 30 mgyml
affinity purified anti-Sec17p, 30 mgyml affinity purified anti-
Sec18p, 75 mgyml affinity purified anti-Ypt7p, 1.2 mM neo-
mycin, and 15 mMmicrocystin-LR.When apyrase was used (66
unityml), the ATP regeneration system was omitted from the
assay. Assays with anti-Sec17p and anti-Sec18p antibodies used
fresh vacuoles that had not been salt washed. A mixture of
equal parts of BJ 3505 and DKY 6281 vacuoles was incubated
at 308C for 10 min with 0.73 mg of IgGymg of vacuoles. After
3 min at 08C, vacuoles were resedimented (8,000 3 g, 80 sec)
and resuspended at 0.3 mgyml in 20 mM PipeszKOH (pH 6.8),
200 mM sorbitol. Fusion reactions (30 ml) contained 20 ml of
vacuoles.
Morphological Vacuole Fusion Assay. Fresh BJ 3505 vacu-
oles were diluted to 0.4 mgyml in 20 mM PipeszKOH (pH 6.8),
200 mM sorbitol, 50 mM KOAc, and 100 mM KCl and
incubated at 308C for 10 min. After centrifugation (8,000 3 g,
80 sec), vacuoles were resuspended at 1.2 mgyml in 20 mM
PipeszKOH (pH 6.8) and 200 mM sorbitol. Ten microliters of
these vacuoles were used in a 30-ml standard fusion reaction,
then stained with 1 ml of 20 mM FM4-64 (32) and visualized
by fluorescence microscopy with TMAXp3200 film (Kodak)
and a Nikon F3 camera.
Purification of I2B from Yeast Cytosol. K91–1A yeast cytosol
(400 ml) was passed through a 6.5 3 17 cm DEAE-cellulose
column in buffer A [20 mM HepeszKOH, pH 6.8y5 mM
MgC12y0.1 mM MnCl2y10% (wt/vol) glycerol] at 6.0 mlymin,
48C. Unbound material was applied at 6.0 mlymin to a 3.8 3
10 cm column of SP-Sepharose Fast Flow in buffer A at 48C.
The column was eluted with 250 ml of buffer A with 200 mM
KCl and a 575 ml linear gradient of 200 mM-550 mM KCl in
buffer A at 1.8 mlymin.
Two peaks of activity emerged. The first peak (45 ml) was
concentrated to 1.5 ml in Amicon Centriprep 10 concentrators
(3,000 3 g, 48C), then incubated at 958C for 4 min and
centrifuged (17,000 3 g, JA18, 48C, 30 min). The supernatant
was applied to a 1.5 3 16 cm Sephacryl S-300HR column in
buffer B [25 mM ethanolamine-CH3COOH, pH 9.4, 10%
(wtyvol) glycerol] at 48C. Two peaks of activity emerged. The
activity with the lower molecular weight (5 ml) was pooled and
loaded at 0.5 mlymin onto a 1.0 3 6.4 cm PBE 94 column
(equilibrated at 48C in buffer B followed by 2 ml of buffer C,
a 1:10 dilution of Polybuffer 96-CH3COOH, pH 6.0). The
column was eluted with buffer C.
Protein Sequencing. Fractions (5 ml) were concentrated to
200 ml by lyophilization, precipitated by methanolychloroform
(23), analyzed by high-Tris SDSyPAGE (20), and transfered to
polyvinylidene difluoride membrane. The protein band was
excised, moistened with 5 ml of methanol, submerged in water,
divided into '1 mm2 pieces, and transfered to a microfuge
tube with 30 ml of digestion buffer (24). Trypsin (Boehringer
Mannheim sequencing grade, 0.1 mg) was added and the
suspension incubated for 18 hr at 378C. A further 20 ml of
digestion buffer was added and the sample shaken for 30 min
followed by centrifugation (238C, 1,700 rpm, 5 min). The
polyvinylidene difluoride pieces were transfered to a Hewlett–
Packard injection vial and washed successively with 50 ml of
digestion buffer and 50 ml of 0.1% (wtyvol) trif luoroacetic
acid, followed by shaking and recentrifugation. The pooled
washes were injected onto an HPLC column and the peptides
were sequenced.
Production of I2B in Escherichia coli. Oligonucleotides
(GIBCOyBRL) with sequences flanking the coding region of
the I2B gene (PBI2) (31) were: 39-HindIII GCGTAAGCT-
TCAGGAATCAAT; PBI2, 59-BspHI CAAGGTCCATCAT-
GACAA. They were used to amplify PBI2 from yeast genomic
DNA (Promega) using DNA polymerization mix (Pharmacia)
and Taq DNA polymerase (GIBCOyBRL). The product was
purified using the QIAquick PCR product purification kit
(Qiagen, Chatsworth, CA).
PBI2-pBAD22 was produced by digestion of the I2B PCR
product with BspHI andHindIII and digestion of pBAD22 (25)
with NcoI and HindIII. DNA fragments were gel purified on
a 1% agarose gel, ligated into the vector with T4 DNA ligase
(26) and transformed into BL21 (DE3) (27).
Purification of I2B from E. coli. I2B-pBAD22yBL21(DE3) was
grown in TB (26) with 100 mgyl amp to OD600 5 0.3, and 200
ml of 20% (wtyvol) arabinose was added. Cells were grown to
OD600 5 1.4, sedimented (5,000 3 g, 10 min), resuspended in
40 ml of buffer D (50 mM KOAc, pH 5.5) with 1 mM
phenylmethylsulfonyl f luoride, and sonicated. The lysate was
centrifuged (37,000 3 g, 30 min, 48C) and the supernatant was
warmed to 808 in a boiling water bath with continuous stirring
followed by 4 min further incubation and centrifugation. The
supernatant was loaded onto a 1.5 3 11.2 cm column of
SP-Sepharose Fast Flow in buffer D at 48C. The column was
eluted with 40 ml of buffer D followed by a linear, 100 ml
gradient of 0–500 mM KCl in buffer D. I2B emerged at '200
mM KCl.
Other Methods. Gel filtration of yeast cytosols (20, 21) and
vacuolar protease B assay (28) were as described. Frozen
vacuoles (100 ml, 60 mg of protein) were incubated at 308C for
3 min with swirling in a final volume of 300 ml with 100 mM
PipeszKOH, pH 6.8, 200 mM sorbitol, 0.15% (wtyvol) TX-100,
and 5 mg of Azocoll. High-Tris SDSyPAGE was as described
(20). Samples were concentrated with chloroformymethanol
(23). Proteins were transfered to a polyvinylidene difluoride
membrane using a PolyBlot apparatus (American Bionetics,
Hayward, CA). I2B was detected with the enhanced chemilu-
minescence kit (Amersham) and enhanced chemilumines-
cence hyperfilm (Amersham) using a rabbit serum produced to
the 12 C-terminal residues of I2B (ENVEEDKEVHTN) (21)
and goat anti-rabbit conjugated to horseradish peroxidase
(Bio-Rad).
RESULTS
Purification of I2B. To identify factors that support in vitro
vacuole fusion, yeast cytosol was passed through a DEAE-
cellulose column and the unbound material was loaded onto a
SP-Sepharose Fast Flow column and eluted with a salt gradi-
ent. The ability of each fraction to catalyze vacuole fusion was
assayed with a limiting amount of Sec18p (ref. 21 and Fig. 3B).
Two peaks of activity emerged that were displaced to either
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side of the bulk of the protein (data not shown). The peak
activity at the lower salt concentration was subjected to
heat-treatment that, surprisingly, stimulated the fusion activity
'3-fold (data not shown). This was probably due to the
removal of inhibitors of the fusion pathway. After gel filtration
through Sepharose S-300HR, two peaks of activity emerged.
The active material of lower molecular weight was purified to
homogeneity by chromatofocusing on a PBE 94 column. The
activity emerged as a single peak with an apparent pI of 7.4
(Fig. 1B). A single protein of '7 kDa comigrated with the
activity (Fig. 1A). This band was digested with trypsin and
peptide fragments were purified by reverse-phase HPLC. One
peptide had the sequence YTIKVPDVLHxNK that is identical
to amino acids 41–53 of I2B, the yeast protease B inhibitor 2
(29).
IB2 is the LMA2 Activity. I2B was originally identified as a
cytosolic protein that inhibits yeast vacuolar proteinase B (30)
and was later found as a component of the LMA1 heterodimer
that can catalyze yeast vacuole fusion (20). Gel filtration has
shown that yeast cytosol contains two low molecular weight
activities termed LMA1 and LMA2 (21). Cytosol derived from
a strain in which both thioredoxin genes have been deleted,
however, only contains the LMA2 activity. Immunoblotting
with anti-I2B antibodies of Sephacryl S-100HR fractions after
gel filtration of wild-type cytosol confirms that I2B elutes with
the LMA1 activity but also shows that the LMA2 fraction
contains a disproportionate amount of I2B relative to its func-
tional activity (Fig. 2A, fraction 52). Moreover, a similar
analysis of cytosol from cells that contain no thioredoxin shows
that I2B elutes exactly with LMA2 (Fig. 2B). Taken together,
these data indicate that I2B and LMA2 are the same protein.
LMA2 Supports Normal Vacuole Fusion. To confirm the
identity of LMA2 (I2B), it was purified (Fig. 3A) from an E. coli
strain in which expression of the PBI2 protein (31) is under the
arabinose promoter. Purified, recombinant LMA2 was incu-
bated with vacuoles and ATP in the presence of a limiting
amount of recombinant Sec18p or Sec18p buffer (Fig. 3B).
LMA2 was far less active in the absence of Sec18p, which alone
yielded no signal. However, LMA2 and Sec18p acted syner-
gistically (Fig. 3B). The LMA2-based reaction is sensitive to
each of the characterized fusion inhibitors (Fig. 3C) that also
inhibit the cytosol-driven vacuole fusion reaction (refs. 14, 16,
and 18 and Fig. 3C).
Since I2B (LMA2) and thioredoxin are subunits of LMA1 (20,
21), we investigated the relative activities of LMA1 and LMA2.
I2B (LMA2) and LMA1 concentrations were determined by
quantitative immunoblotting with anti-I2B antibody (data not
shown), and vacuole fusion assays were performed with either
LMA1 (containing 75 ng of I2B) or 75 ng of purified I2B itself.
LMA2 did not support fusion as rapidly as an equivalent
amount of LMA1 (Fig. 4A). Although the extent of fusion
catalyzed by LMA1 or LMA2 at low I2B concentrations was
similar (Fig. 4B), the yield of the LMA1-driven reaction
continued to increase with the protein concentration while that
of the LMA2-driven reaction reached a plateau.
Since I2B can inhibit vacuolar protease B, it might catalyze
vacuole fusion by functioning as a protease inhibitor. To test
this, vacuoles were prepared from BJ3505 cells that contain
neither protease A nor protease B and were incubated with
Sec18p or with Sec18p and LMA2. At the start of the reaction,
an aliquot of each mixture was placed on ice to prevent vacuole
fusion. Upon completion of the reaction, aliquots were stained
FIG. 1. I2B promotes vacuole fusion. (A) Yeast cytosol was sub-
jected to successive steps of DEAE-cellulose, SP-Sepharose Fast Flow,
Sephacryl S-300HR chromatography, and chromatofocusing. Alter-
nate fractions (200 ml) of the latter were analyzed by high-Tris
SDSyPAGE followed by staining with Coomassie brilliant blue R.
Positions of molecular weight markers are shown on the right and of
I2B on the left. (B) The pH of alternate fractions and their ability to
drive vacuole fusion in the presence of limiting amounts of Sec18p was
determined.
FIG. 2. I2B is LMA2. Previously characterized (20) fractions from
gel filtration of wild-type (A) or thioredoxin double-deletion cytosol
(B) that had been assayed for protein and vacuole fusion activity (20)
were assayed for I2B by immunoblot.
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with the vacuole specific f luorophore FM4-64 (32). Little
vacuole fusion was observed in the presence of Sec18p (Fig.
5B) compared with the ice control (Fig. 5A). However, after
incubation with both Sec18p and LMA2, large vacuoles were
seen, indicating that fusion had occurred (Fig. 5C).
To confirm that the activity of LMA2 as a protease inhibitor
is unrelated to its ability to support vacuole fusion, reactions
were performed in the presence of chymostatin, a serine
protease inhibitor. Chymostatin does not inhibit protease A
(33), an aspartate protease, but is a strong inhibitor of protease
B, a serine protease. Chymostatin should therefore not prevent
the maturation of pro-alkaline phosphatase (that largely de-
pends on protease A) after vacuole fusion. Proteinase B
activity is 93% inhibited by 7pM chymostatin (Fig. 6A) in an
assay (33) that is highly specific for this protease (33) and that
contains the same vacuole concentration as a fusion reaction.
At the same concentration, chymostatin does not stimulate
vacuole fusion (Fig. 6A). In contrast, LMA2 stimulates vacuole
fusion at concentrations that completely inhibits protease B. A
20-fold lower concentration of LMA2 inhibits protease B by
97% but does not support vacuole fusion (Fig. 6A). Thus
inhibition of protease B activity does not lead to vacuole
fusion, and the activity of LMA2 in supporting vacuole fusion
does not correlate with its inhibition of protease B.
To test whether the binding of thioredoxin to I2B alters its
ability to inhibit protease B, the protease B activity was assayed
with LMA1 or with LMA2 that contained equivalent amounts
of I2B (see above). While LMA1 can inhibit protease B, it did
so far less effectively than LMA2 (Fig. 6B). The fact that
LMA1 is more effective than LMA2 in promoting vacuole
fusion (Fig. 4), but is less efficient in inhibiting protease B (Fig.
6B) shows that LMA2 does not support vacuole fusion by
inhibiting protease B.
Yeast Cytosol Contains at Least One Other Heat-Stable
Fusion Factor. Yeast cytosol contains heat stable factors that
can stimulate vacuole fusion (17) and LMA2 was purified from
cytosol using a procedure that involved a heating step. To
determine whether LMA2 alone is responsible for the activity
of HCS, cytosols were prepared from a mutant yeast strain
(YPS19) in which the I2B gene had been deleted (31) and from
FIG. 3. Recombinant I2B drives vacuole fusion along the Sec18p-
dependent pathway. (A) LMA2 (I2B) was purified from a recombinant
E. coli strain and analyzed by high-Tris SDSyPAGE and silver-
staining. (B) Vacuole fusion reactions contained LMA2 in the pres-
ence or absence of Sec18p (see Materials and Methods). (C) Vacuole
fusion was assayed in the presence of Sec18p and either 80 mg of yeast
cytosol or 75 ng of LMA2. Assays were performed in the absence (no
addition) or presence of various inhibitors of vacuole fusion (see
Materials and Methods). The ATP-only background was 0.05 units.
FIG. 4. LMA2 is less efficient at promoting vacuole fusion than
LMA1. (A) Aliquots were removed from the equivalent of ten regular
fusion assays containing equal amounts of either LMA1 or LMA2 and
placed on ice. Each aliquot was assayed for alkaline phosphatase
activity. (B) Vacuoles were incubated with Sec18p and LMA1 or
LMA2 containing equivalent amounts of I2B. The data are the average
of three experiments 6 SD and are shown as a percentage of the
maximal fusion signal (A, 0.98 units; B, 1.05 units).
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its parental strain (YS18). YS18 and YPS19 HCS had similar
fusion activities (Fig. 7A), showing that I2B is not the only
heat-stable cytosolic factor.
One such heat-stable activity is a ‘‘Sec18p-activating factor’’
(17). Preincubation of vacuoles with antibodies to Sec18p
renders them inactive unless a subsequent fusion reaction is
supplemented with active Sec18p, Sec18p-immunodepleted
cytosol, or HCS (17). However, we have been unable to detect
any Sec18p-activating factor activity associated with LMA2
(data not shown). HCS from yeast strains YS18 and YPS19
were equally able to overcome the Sec18 antibody block,
confirming that the LMA2 and Sec18p-activating factor ac-
tivities are distinct (Fig. 7B).
DISCUSSION
We recently identified LMA1, a low-molecular weight het-
erodimeric protein from S. cerevisiae that participates in
vacuole inheritance both in vivo and in our in vitro assay (20).
One component of this complex is thioredoxin while the other
is I2B (21), demonstrating that I2B has a second, novel function.
Here we report the independent purification of uncomplexed
I2B as an activity that supports vacuole fusion in vitro. Deletion
of both TRX1 and TRX2 eliminates LMA1 but not LMA2
activity (20). I2B from the thioredoxin double-mutant copurifies
with the LMA2 activity and expression of the cloned gene in
E. coli yields a protein of full activity, demonstrating that the
LMA2 is I2B, free of thioredoxin.
Deletion of the I2B gene yields a vac phenotype in vivo (21).
Furthermore, the LMA2-driven reaction is sensitive to all of
the tested inhibitors of the cytosol-driven reaction. Since
LMA2 can drive the fusion of vacuoles that lack protease B,
it does not function in vacuole fusion by means of its protease
B inhibitor activity. Furthermore, inhibition of vacuolar pro-
tease B using chymostatin does not stimulate vacuolar fusion,
and low levels of LMA2 that almost completely inhibit pro-
tease B are insufficient to support the fusion reaction. It is also
unlikely that LMA2 could be inactivating other proteases and
so stimulate vacuole fusion for three reasons. First, I2B, as a
noncompetitive inhibitor of protease B, must bind to the
protease at a point other than its active site, and thus is unlikely
to inhibit other proteases by binding to their catalytic clefts.
Second, I2B has a very high (nM) affinity for protease B (1) and
so is an unlikely candidate for a broad-spectrum protease
inhibitor; it has almost no inhibitory activity to proteinase A or
carboxypeptidase Y (1). Third, we have never observed stim-
ulation of fusion by other protease inhibitors.
LMA2 is not the only heat-stable active factor in yeast
cytosol that can support vacuole fusion. Heated cytosol su-
pernatants from cytosol lacking I2B can still efficiently support
vacuole fusion, indicating that at least one other heat-stable
factor is involved. This activity may be the Sec18p-reactivating
factor that may act by recruiting membrane-bound Sec18p into
an active fusion complex (17). This activity is distinct from
LMA2. In addition, the identity of the high molecular weight
activity of yeast cytosol (20) has yet to be established.
FIG. 5. LMA2 supports the fusion of vacuoles lacking protease B.
Fresh, salt-washed vacuoles were incubated for 2 hr at 08C (A) or 278C
(B and C) in the presence of Sec18p (B) or Sec18p and LMA2 (A and
C). Vacuoles were stained with FM4-64 and visualized by fluorescence
microscopy. (Bar 5 4 mm.)
FIG. 6. Inhibition of protease B does not promote vacuole fusion.
(A) Vacuoles were assayed for protease B activity or fusion in the
absence of added reagents or in the presence of 7pM chymostatin, 2.5
mgyml LMA2, a mixture of both or 125 ngyml of LMA2 alone (Low
LMA2). The data were expressed as a percentage of maximal protease
B activity or fusion activity (0.42 unit). (B) Vacuoles were assayed for
protease B activity in the presence of LMA1 or LMA2 that contained
equivalent amounts of I2B. Data are presented as a percent of protease
activity in the absence of added protein and are the average of two
experiments.
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Although LMA2 is capable of supporting vacuole fusion in
the absence of thioredoxin, its activity is substantially lower
than that of LMA1.We have as yet been unable to demonstrate
any fusion activity for uncomplexed yeast thioredoxin in our
system (Z.X. and P.S., unpublished observations).
Since the redox activity of thioredoxin is not required for
LMA1 function (21) and LMA2 has no known catalytic
activity, we postulate that these proteins function as a ligand
for a membrane-bound receptor. We are currently attempting
to identify this putative receptor, which should yield a signif-
icant insight into the mode of action of LMA1 and LMA2.
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FIG. 7. Yeast cytosol contains heat-stable activities other than
LMA2. (A) Frozen, salt-washed vacuoles were incubated with ATP
alone, 30 mg of I2B-wild-type cytosol (K91-1A), 1.2 mg of I2B-wild-type
HCS, or 1.2 mg of I2B-deletion HCS. Data were normalized to the
maximal (cytosol) signal (1.25 units) and the average of four experi-
ments is shown 6 SD. (B) Fresh vacuoles that had not been salt-
washed were preincubated with preimmune or anti-Sec18p IgG. After
removal of the antibody, vacuoles were incubated with ATP and 30 mg
of cytosol, either with or without immunodepletion of Sec17p or
Sec18p, or with 1.2 mg of HCS from wild-type or I2B-deletion cytosol.
The average of two experiments is shown.
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